VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2021 | Updates on the SINTART2 trial in patients with inoperable sinonasal epithelial tumors

Paolo Bossi, MD, University of Brescia, Brescia, Italy, presents data from the Phase II Prospective SINTART2 clinical trial (NCT02099188), evaluating induction chemotherapy followed by radiation therapy with photons or heavy ion radiotherapy in inoperable patients with sinonasal epithelial tumors with selected histological subtypes. Patients with these rare tumours have a very poor prognosis. Dr Bossi explains that although the data is not showing significant improvements in the survival rate, some patients respond well to post-induction chemotherapy. It is therefore important to identify the factors that can predict whether patients will respond the induction chemotherapy and conduct further research to find treatment options for patients that do not respond to this treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.


Dr Bossi reports consultant/advisory board participation for BMS, MSD, Merck, Sanofi.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter